Sodium ion battery has become the "new darling" of the capital market. The best time to plant a tree was ten years ago, followed by now. It is undeniable that at the present stage, the industrialization of sodium ion battery is faced with difficult problems such as energy density, cycle life and supporting industry chain, but with the active exploration and development of enterprises, breaking through the problem of "sticking neck" and preemptively laying out the next tuyere of the battery, maybe it's the best time.
TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) swung into profit last year with net profit of NT$775 million (US$27.1 million) after it received a bonus payment from China’s Zhejiang Medicine Co (浙江醫藥集團), it said yesterday.
Last year marked TaiGen’s first profitable year since 2017, as it registered net losses of NT$343 million in 2018, NT$295 million in 2019 and NT$404 million in 2020.
Despite reporting earnings per share of NT$1.08 for last year, the company’s board of directors has proposed not to distribute a cash dividend this year, TaiGen said.
The company attributed the improvement in its balance sheet to a payment of NT$1.29 billion